Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: Biotechwantabe who wrote (3135)	11/4/2020 7:39:11 PM
From: Felix B	Read Replies (1) \| Respond to of 3557

Why next week for EUA? Regardless, I don't see a big spike in SP given they stopped enrolling in the high risk patients but still plenty of demand even without those patients.

To: Biotechwantabe who wrote (3135)	11/5/2020 8:16:52 AM
From: Biotechwantabe	Read Replies (1) \| Respond to of 3557

On partnership and row sales: Eylea US 1318m +11% Row 780m +7(bayer is a lazy partner) Dupi Us 851 Row 221 (sanofi is not performing) Cov2 Will Roche perform? It’s about time for regeneron to accept responsibility for row sales vs leaving it to partners. Either that or sellout. Another example of not investing enough in themselves. I really shouldn’t complain as I’m making a fortune on their stock. But I think they need to change their approach.